• 1
    Kraemer DF, Fortin D, Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and futures directions. Curr Neurol Neurosci Rep. 2002; 2: 216224.
  • 2
    Earnest F 4th, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology. 1988; 166: 823827.
  • 3
    Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery. 1999; 45: 12791291.
  • 4
    Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg. 1978; 49: 333343.
  • 5
    Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303: 13231329.
  • 6
    Holsi P, Sappino AP, de Tribolet N, Dietrich PY. Malignant glioma: should chemotherapy be overthrown by experimental treatments? Ann Oncol. 1998; 6: 589600.
  • 7
    Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002; 17: 36443650.
  • 8
    Fortin D, Neuwelt EA. Therapeutic manipulation of the blood-brain barrier. Neurobase-neurosurgery. 1st ed. Medlink CD-ROM, 2003.
  • 9
    Bradbury MWB. Appraisal of the role of endothelial cells and glia in barrier breakdown. In: SucklingAJ, RumsbyMG, BradburyMWB, editors. The blood-brain barrier in health and disease. Chichester: Ellis Horwood, 1986: 128129.
  • 10
    Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998; 42: 10831100.
  • 11
    Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab. 1997; 17: 713731.
  • 12
    Rapoport SI, Hori M, Klatzo I. Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol. 1972; 223: 323331.
  • 13
    NeuweltEA, editor. Implications of the blood-brain barrier and its manipulation. vols. 1, 2. New York: Plenum Press, 1989.
  • 14
    Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000; 88: 637647.
  • 15
    Fortin D, McAllister LD, Nesbit G, et al. Unusual cervical spine cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide with osmotic blood brain-barrier disruption in the vertebral artery. Am J Neuroradiol. 1999; 20: 17941802.
  • 16
    Saris SC, Blasberg RG, Carson RE. Intravascular streaming during carotid infusion: demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg. 1991; 74: 763772.
  • 17
    Macdonald DR, Cascino TL, Schold SC Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 7: 12771280.
  • 18
    Estève J, Benhamou E, Raymond L. Méthodes statistiques en épidémiologie descriptive. [Statistical methods in descriptive epidemiology.] Les éditions INSERM. Paris: INSERM, 1993.
  • 19
    Valleron A-J. Introduction à la biostatistique. [Introduction to biostatistics.] Paris: Masson, 1998.
  • 20
    Scott CB, Scarantino C, Urtason R, et al. Validation and predictive power of RTOG recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998; 40: 5155.
  • 21
    Doolittle ND, Tyson RM, Lacy C, et al. Potential role of delayed high-dose sodium thiosulfate as protectant against carboplatin-based thrombocytopenia in patients with malignant brain tumors. [abstract]. Neuro-Oncology. 2001; 3: 357.
  • 22
    Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant agent against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001; 7: 493500.
  • 23
    Pardridge WM. Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol. 2001; 59: 3540.
  • 24
    Rapaport SI, Fredericks WR, Ohno K, Pettigrew KD. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol. 1980; 238: R421R431.
  • 25
    Markowsky SJ, Zimmerman CL, Tholl D, Soria I, Castillo R. Methotrexate disposition following disruption of the blood-brain barrier. Ther Drug Monit. 1991; 13: 2431.
  • 26
    Robinson PJ, Rapoport SI. Model for drug uptake by brain tumors: effects of osmotic treatment and of diffusion in brain. J Cereb Blood Flow Metab. 1991; 11: 165168.
  • 27
    Neuwelt EA, Specht HD, Barnett PA, et al. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery. 1987; 20: 885895.
  • 28
    Yang W, Barth RF, Carpenter DE, Moeschberger ML, Goodman JH. Enhanced delivery of boronophenylalanine by means of intracarotid injection and blood-brain barrier disruption for neutron capture therapy. Neurosurgery. 1996; 38: 985992.
  • 29
    Roman-Goldstein S, Clunie DA, Stevens J, et al. Osmotic blood-brain barrier disruption: CT and radionuclide imaging. Am J Neuroradiol. 1994; 15: 581590.
  • 30
    Siegal T, Rubinstein R, Bokstein F, et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg. 2000; 92: 599605.
  • 31
    Muldoon LL, Nilaver G, Kroll RA, et al. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol. 1995; 147: 18401851.
  • 32
    Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N. Quantification of early blood-brain barrier disruption by in situ brain perfusion technique. Brain Res Prot. 2001; 8: 126131.
  • 33
    McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000; 46: 5161.
  • 34
    Fortin M, Macdonald D, Stitt L, Cairncross GJ. PCV chemotherapy for oligodendroglioma, anaplastic oligodendroglioma and mixed tumors: a retrospective analysis of 53 cases to determine prognostic factors for response and survival. Can J Neurol Sci. 2001; 28: 215233.
  • 35
    Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988; 23: 460464.
  • 36
    Fortin D. The blood-brain barrier should not be underestimated in neuro-oncology. Rev Neurol. 2004; 160: 523532.